{"id":10250,"date":"2025-10-06T09:14:41","date_gmt":"2025-10-06T07:14:41","guid":{"rendered":"https:\/\/shams-alyaoum.com\/en\/?p=10250"},"modified":"2025-10-06T09:14:42","modified_gmt":"2025-10-06T07:14:42","slug":"hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena","status":"publish","type":"post","link":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/","title":{"rendered":"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical leader, have signed exclusive licensing agreements across the Middle East and North Africa (MENA) region.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The new agreements will broaden access to cutting-edge and affordable biologics through the introduction of six biosimilar treatments to the region. This also marks a significant advancement in expanding access to biosimilar treatments across key therapeutic areas, including allergic diseases, ophthalmology, skeletal-related disorders, immune diseases and oncology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By offering high-quality, cost-effective alternatives to complex biologics, Hikma is enabling broader patient access to life-saving and life enhancing therapies that were previously restricted due to high costs or limited availability. Under the agreements, Hikma will hold exclusive commercialisation rights across all MENA markets, while Celltrion will be responsible for the development, manufacturing and supply of the treatments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With these new agreements, Hikma solidifies its position as a leading provider of biosimilars in the MENA region and takes a pivotal step in its broader biotech strategy to enhance patient outcomes, reduce healthcare system burdens, and transform treatment standards in hospitals across MENA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mazen Darwazah, Hikma\u2019s Executive Vice Chairman and President of MENA<\/strong>, said: \u201cWe are proud to expand our partnership with Celltrion Inc., reinforcing our shared commitment to improving access to high quality, biosimilar treatments. These treatments have the potential to significantly improve quality of life for patients living with chronic, debilitating, or life-threatening conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The addition of these biosimilars enhances Hikma\u2019s ability to serve hospital channels with a comprehensive portfolio of injectables and biologics, reinforcing its ambition to become the top hospital player in the region.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical leader, have signed exclusive licensing agreements across the Middle East and North Africa (MENA) region. The new agreements will broaden access to cutting-edge and affordable biologics through the introduction of six biosimilar treatments to the region. This also &hellip;<\/p>\n","protected":false},"author":2,"featured_media":10251,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-10250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA - Magazine Shams Al Yaoum<\/title>\n<meta name=\"description\" content=\"Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA - Magazine Shams Al Yaoum\" \/>\n<meta property=\"og:description\" content=\"Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical\" \/>\n<meta property=\"og:url\" content=\"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/\" \/>\n<meta property=\"og:site_name\" content=\"Magazine Shams Al Yaoum\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T07:14:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-06T07:14:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2025\/10\/Hikma-LOGO__1759726852.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"666\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"shamsalyaoum\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"shamsalyaoum\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/\"},\"author\":{\"name\":\"shamsalyaoum\",\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/#\\\/schema\\\/person\\\/6e4dae56c61a28d2d84c342a9a53d199\"},\"headline\":\"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA\",\"datePublished\":\"2025-10-06T07:14:41+00:00\",\"dateModified\":\"2025-10-06T07:14:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Hikma-LOGO__1759726852.jpg\",\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/\",\"url\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/\",\"name\":\"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA - Magazine Shams Al Yaoum\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Hikma-LOGO__1759726852.jpg\",\"datePublished\":\"2025-10-06T07:14:41+00:00\",\"dateModified\":\"2025-10-06T07:14:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/#\\\/schema\\\/person\\\/6e4dae56c61a28d2d84c342a9a53d199\"},\"description\":\"Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/#primaryimage\",\"url\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Hikma-LOGO__1759726852.jpg\",\"contentUrl\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Hikma-LOGO__1759726852.jpg\",\"width\":1000,\"height\":666},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/\",\"name\":\"Magazine Shams Al Yaoum\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/#\\\/schema\\\/person\\\/6e4dae56c61a28d2d84c342a9a53d199\",\"name\":\"shamsalyaoum\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g\",\"caption\":\"shamsalyaoum\"},\"url\":\"https:\\\/\\\/shams-alyaoum.com\\\/en\\\/author\\\/shamsalyaoum\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA - Magazine Shams Al Yaoum","description":"Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/","og_locale":"en_US","og_type":"article","og_title":"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA - Magazine Shams Al Yaoum","og_description":"Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical","og_url":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/","og_site_name":"Magazine Shams Al Yaoum","article_published_time":"2025-10-06T07:14:41+00:00","article_modified_time":"2025-10-06T07:14:42+00:00","og_image":[{"width":1000,"height":666,"url":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2025\/10\/Hikma-LOGO__1759726852.jpg","type":"image\/jpeg"}],"author":"shamsalyaoum","twitter_card":"summary_large_image","twitter_misc":{"Written by":"shamsalyaoum","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/#article","isPartOf":{"@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/"},"author":{"name":"shamsalyaoum","@id":"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/6e4dae56c61a28d2d84c342a9a53d199"},"headline":"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA","datePublished":"2025-10-06T07:14:41+00:00","dateModified":"2025-10-06T07:14:42+00:00","mainEntityOfPage":{"@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/"},"wordCount":279,"image":{"@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/#primaryimage"},"thumbnailUrl":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2025\/10\/Hikma-LOGO__1759726852.jpg","articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/","url":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/","name":"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA - Magazine Shams Al Yaoum","isPartOf":{"@id":"https:\/\/shams-alyaoum.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/#primaryimage"},"image":{"@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/#primaryimage"},"thumbnailUrl":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2025\/10\/Hikma-LOGO__1759726852.jpg","datePublished":"2025-10-06T07:14:41+00:00","dateModified":"2025-10-06T07:14:42+00:00","author":{"@id":"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/6e4dae56c61a28d2d84c342a9a53d199"},"description":"Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical","breadcrumb":{"@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/#primaryimage","url":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2025\/10\/Hikma-LOGO__1759726852.jpg","contentUrl":"https:\/\/shams-alyaoum.com\/en\/wp-content\/uploads\/2025\/10\/Hikma-LOGO__1759726852.jpg","width":1000,"height":666},{"@type":"BreadcrumbList","@id":"https:\/\/shams-alyaoum.com\/en\/hikma-and-celltrion-strengthen-partnership-to-expand-biosimilar-access-in-mena\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/shams-alyaoum.com\/en\/"},{"@type":"ListItem","position":2,"name":"Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA"}]},{"@type":"WebSite","@id":"https:\/\/shams-alyaoum.com\/en\/#website","url":"https:\/\/shams-alyaoum.com\/en\/","name":"Magazine Shams Al Yaoum","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/shams-alyaoum.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/shams-alyaoum.com\/en\/#\/schema\/person\/6e4dae56c61a28d2d84c342a9a53d199","name":"shamsalyaoum","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11774fd6260846ea4d3230345b47c868eaffb0fe76386b1a8b3cc24c8dc91f3d?s=96&d=mm&r=g","caption":"shamsalyaoum"},"url":"https:\/\/shams-alyaoum.com\/en\/author\/shamsalyaoum\/"}]}},"_links":{"self":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts\/10250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/comments?post=10250"}],"version-history":[{"count":2,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts\/10250\/revisions"}],"predecessor-version":[{"id":10253,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/posts\/10250\/revisions\/10253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/media\/10251"}],"wp:attachment":[{"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/media?parent=10250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/categories?post=10250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/shams-alyaoum.com\/en\/wp-json\/wp\/v2\/tags?post=10250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}